Inhibikase Therapeutics

Company snapshot

We are a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit”, has been implicated. Our lead product candidate is IKT-0

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Inhibikase Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Inhibikase Therapeutics.

1. Jun 8, 2026 Clinical update

   IKT-001-201 — Phase 3

2. Jun 8, 2026 Clinical update

   Imatinib Mesylate — Phase 1

3. May 23, 2026 Clinical update

   IKT-001 — Phase 3

4. May 23, 2026 Clinical update

   IkT-001Pro — Phase 2

5. Aug 15, 2023 Patent grant

   Compositions and methods for inhibiting kinases

View all clinical trial activity →

• What is Inhibikase Therapeutics?

  Inhibikase Therapeutics is a biotech organization headquartered in Wilmington, USA. It trades on NYSE under ticker IKT. Primary therapeutic focus areas include Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH). NovaPharmaNews links 4 clinical program(s), 0 dr

• Is Inhibikase Therapeutics publicly traded?

  Yes. Inhibikase Therapeutics is listed with ticker IKT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Inhibikase Therapeutics develop or market?

  We link 5 drug profile(s) where Inhibikase Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/inhibikase-therapeutics#company-drugs.

• What are the latest developments for Inhibikase Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Inhibikase Therapeutics focus on?

  Inhibikase Therapeutics focuses on Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) based on our analysis of their pipeline programs and drug development activities.